A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Cow urine to be used in medicines and treatment of cancer: Ashwini Choubeyon September 7, 2019 at 7:41 pm
He said that the Health Ministry is studying a proposal to include cancer treatment under the Ayushman Bharat Prime Minister Jana Arogya Yojana Tamil Nadu: Ashwini Kumar Choubey, the Minister of State ...
- Tobacco cessation after cancer diagnosis: Declaration from the IASLCon September 7, 2019 at 10:07 am
... of smoking after the diagnosis of cancer also has a substantial effect on increased cancer treatment costs, according to the Declaration. The IASLC Tobacco Control and Smoking Cessation ...
- Cannabis During Breast Cancer Treatment: What Are The Benefits?on September 6, 2019 at 5:10 pm
A cancer diagnosis is a life-changing event. From the confusion of understanding the road ahead to the hectic schedule of treatment protocols and never-ending appointments, many individuals ...
- Prostate Cancer Treatment – High Intensity Focused Ultrasoundon September 6, 2019 at 12:18 pm
According to the American Cancer Society, prostate cancer is the most common cancer among men. Thanks to technology there's been a breakthrough in treating this disease. It's called High ...
- When Treatment Is Over: Actor Sterling Brown Puts a Spotlight on Life After Canceron September 6, 2019 at 10:26 am
Sign on to social media on any given day and you’re likely to encounter a certain genre of video posts — the last-day-of-treatment post. In it, someone who’s been undergoing treatment for cancer can ...
- Global Blood and Bone Marrow Cancer Treatment Market to 2027 by Indication, Therapy, Geography, Competitive Landscape - ResearchAndMarkets.comon September 6, 2019 at 6:27 am
The "Global Blood and Bone Marrow Cancer Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019-2027" ...
- Taylor Swift surprises fan by donating $10,000 for her cancer treatmenton September 6, 2019 at 5:25 am
American pop-star Taylor Swift recently surprised one of her fans by donating $10,000 for her stage four cancer treatment. The 29-year-old Grammy winner penned a sweet note on her 16-year-old fan ...
- IMS Reports the Multidisciplinary Approaches to Minimally Invasive Cancer Treatment Using JCI MN Colloidal Iodineon September 6, 2019 at 1:00 am
Ryusuke Fujiki, Clinical Head and President of Fujiki Hospital, lectured about multidisciplinary approaches which are getting remarkable effect to minimally invasive cancer treatment using JCI MN ...
- More targeted, less toxic: The golden future of cancer treatmenton September 6, 2019 at 12:11 am
Researchers have engineered gold-based molecules that target cancer cells and leave healthy cells unharmed, in a critical step towards precision cancer drugs with fewer toxic side effects.
via Bing News